Search
Oxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigational[A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316] … [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties.
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalC-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a ...
Valrubicin
go.drugbank.com/drugs/DB00385ApprovedUsed in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.
Phenindione
go.drugbank.com/drugs/DB00498ApprovedInvestigationalPhenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Categories: Vitamin K AntagonistsLutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalLutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots.
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
V590
go.drugbank.com/drugs/DB16437ExperimentalBy teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583].
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalBy inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnThese are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
MF-300
go.drugbank.com/drugs/DB32060InvestigationalAs a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]